Peptide Therapy Tesamorelin
Provider evaluation · Appropriate testing · Ongoing monitoring
This Is A Metabolic Peptide, Not A Weight-Loss Shot
Tesamorelin is a growth-hormone-releasing peptide, originally developed and FDA-approved to reduce visceral fat. Patients ask about it for 3 reasons: stubborn abdominal fat that doesn’t respond to diet or exercise, muscle loss that comes with aging or weight loss, and lipid levels that have started trending in the wrong direction. Tesamorelin is not a GLP-1 medication and does not work by suppressing appetite. It appears to stimulate the body’s own growth hormone production, which is associated with reduced visceral fat and preserved lean muscle. It is not a substitute for diet, exercise, or the GLP-1 therapies we prescribe separately; it works through a different mechanism entirely. At T Clinics USA, tesamorelin is prescribed after an evaluation and lab work, and it is rarely prescribed alone. Most people see better results when it is paired with the rest of their hormone and metabolic picture, because body composition depends on more than 1 input. Your provider determines whether it is appropriate for you, at what dose, and for how long.
What You Get Beyond The Prescription
Tesamorelin works inside a plan, not on its own. Here is what that plan looks like at T Clinics USA in Naples, Fort Myers, and Coral Springs.
How It Works
Tesamorelin Care At T Clinics USA
You have questions, we have answers.
Where Tesamorelin Stands Today
Tesamorelin is FDA-approved, sold under the brand name Egrifta, for reducing excess visceral fat in a specific patient population. When T Clinics USA prescribes tesamorelin outside that approved use, or as a compounded medication, it is prescribed off-label, and compounded medications are not FDA-approved. We tell patients directly which situation applies to their plan rather than letting the FDA-approval headline stand in for the whole picture.